Title : Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.

Pub. Date : 2021 Jan 4

PMID : 33502484






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Importance: Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has shown a significant response in steroid-refractory chronic graft-vs-host disease (SR-cGVHD), a major cause of morbidity and mortality in individuals who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). ruxolitinib Janus kinase 1 Homo sapiens